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Objective
To analyze self-reported adherence to antiretroviral regimens containing ritonavir-boosted protease inhibitors, non-nucleoside
reverse transcriptase inhibitors (NNRTI), raltegravir, and maraviroc.
Methods
Overall, 372 consecutive subjects attending a reference center for HIV treatment in Florence, Italy, were enrolled in the study,
from December 2010 to January 2012 (mean age 48 years). A self-report questionnaire was filled in. Patients were defined as
‘‘non-adherent’’ if reporting one of the following criteria:B90% of pills taken in the last month, ]1 missed dose in the last
week, spontaneous treatment interruptions reported, or refill problems in the last 3 months. Gender, age, CD4, HIV-RNA, years
of therapy, and type of antiretroviral regimen were analyzed with respect to adherence.
Results
At the time of the questionnaire, 89.8% of patients had B50 copies/mL HIV-RNA and 14.2% were on their first combined
antiretroviral therapy. 57% of patients were prescribed a regimen containing ritonavir boosted protease inhibitors (boosted PI),
41.7% NNRTI, 17.2% raltegravir, and 4.8% maraviroc; 49.5% of the subjects were on bis-in-die regimens, while 50.5% were on
once-daily regimens, with 23.1% of these on the single tablet regimen (STR): tenofovir/emtricitabine/efavirenz. The non-
adherence proportion was lower in NNRTI than in boosted-PI treatments (19.4% vs 30.2%), and even lower in STR patients
(17.4%). In multivariable logistic regression, patients with the NNRTI regimen (OR: 0.56, 95% CI: 0.340.94) and the STR (OR:
0.45, 95% CI: 0.220.92) reported lower non-adherence. Efavirenz regimens were also associated with lower non-adherence
(OR: 0.42, 95% CI: 0.210.83), while atazanavir/ritonavir regimens were associated with higher non-adherence. No other
relation to specific antiretroviral drugs was found. A higher CD4 count, lower HIV-RNA, and older age were also found to
be associated with lower non-adherence, while a longer time on combined antiretroviral therapy was related to higher
non-adherence.
Conclusion
In conclusion, older age, higher CD4 cell counts, lower HIV-RNA viral loads, and the use of STR are all related to lower non-
adherence. In particular, the use of STR maintains an advantage in improving adherence with respect to other cARTs, even with
the availability of new, well-tolerated antiretroviral drugs and drug classes in recent years.
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